

**Meeting Minutes**  
**North Dakota Medicaid Drug Use Review (DUR) Board**  
**Meeting Date:** September 6<sup>th</sup>, 2023  
**Time and Location:** 1:00 pm CST in Bismarck, North Dakota

**Call to Order:**

A regular quarterly meeting of the North Dakota Medicaid Drug Use Review (DUR) Board meeting was convened at 1:03 pm CST. with pro tem Presiding Officer T. Schmidt presiding, and DUR Board Coordinator, C. Stauter recording minutes.

**Roll Call:**

*Board Members Voting:*

*Present:* Gabriela Balf, Kurt Datz, Andrea Honeyman, Jennifer Iverson, Laura Kroetsch, Kevin Martian, Kristen Peterson, Tanya Schmidt, Amy Werremeyer

*Absent:* Stephanie Antony, Josh Askvig

*Quorum Present:* Yes

*Board Members Non-Voting:*

*Present:* Kathleen Traylor

*Medicaid Pharmacy Department:*

*Present:* Jeff Hostetter, Brendan Joyce, Alexi Murphy, LeNeika Roehrich

**Approval of Meeting Minutes:**

*Motion:* Moved by A. Werremeyer to approve the minutes of the June 7<sup>th</sup>, 2023 meeting, motion was seconded by K. Martian. **Motion carried.**

The minutes of the June 7<sup>th</sup>, 2023, meeting were approved as distributed.

**Reports:**

*Administrative Report: Member Update* provided by C. Stauter  
C. Stauter introduced the new Board Member K. Datz.

*Administrative Report: Unwinding* by A. Murphy

A. Murphy shared with the Board trends regarding unwinding. This information can be found in the handout.

*Administrative Report: RSV Prophylaxis* by A. Murphy

A. Murphy presented immunization recommendations and North Dakota's Medicaid plan for RSV Prophylaxis. This information can be found in the handout. Testimony was provided by Julie Gilpin from SOBI on Synagis.

*Administrative Report: Humira Biosimilars* by A. Murphy

A. Murphy discussed biosimilars of Humira with the Board; North Dakota Medicaid will continue to prefer Humira brand name.

*Financial Report: Budget* provided by B. Joyce

B. Joyce shared with the Board the expected trends of unwinding and the impact on rebates of insulin price decreases.

*Financial Report: Top Drugs* provided by B. Joyce

B. Joyce presented the quarterly review of the top 25 drugs based on total number and cost of claims and the top 15 therapeutic classes based on number and cost of claims. This report can be found in the handout.

*Clinical Report: Annual PDL Review Criteria Update* by C. Stauter

C. Stauter discussed updates to the following sections in the PDL: Gout, Chronic Kidney Disease, Heart Failure, Long-Acting Opioid Analgesics, Opioid Use Disorder, Clostridioides difficile-associated diarrhea (CDAD), and Medications over \$3000. These changes can be found in the handout. Testimony was provided by Christopher Ngai from Callidaitas Therapeutics on Tarpeyo, Jessica Jay from Indivior on Sublocade, and Jake Nichols from US World Meds on ZIMHI and Lucemyra.

*Retrospective Drug Utilization Review (RDUR) Report* by C. Stauter

C. Stauter reviewed the quarterly RDUR criteria that were selected for review of each month. This material can be found in the handout.

*Unfinished business:*

*Update to Hyperparathyroidism (Sensipar)* provided by A. Murphy

A. Murphy discussed the changes to the hyperparathyroidism section to the PDL. These changes can be found in the handout.

*New business:*

*First Reviews* provided by C. Stauter

C. Stauter presented an overview of diuretics (triamterene) and menopause (Veozah). The presented material can be found in the handout. Testimony was provided by Jeenal Choksi from Astellas on Veozah.

*Motion:* Moved by K. Martian to draft prior authorization for triamterene, motion was seconded by A. Werremeyer. **Motion carried.**

*Motion:* Moved by A. Werremeyer to draft prior authorization for menopause, motion was seconded by A. Honeyman. **Motion carried.**

*Retrospective Drug Utilization Review (RDUR) Criteria Recommendations:*

RDUR criteria recommendations were reviewed. The presented material can be found in the handout.

*Motion:* Moved by K. Martian to approve the RDUR criteria, motion was seconded by K. Peterson. **Motion carried.**

**Announcements:**

Next meeting is December 6th, 2023.

**Adjournment:**

Meeting adjourned by T. Schmidt at 2:26 pm CST.

**Date of Minutes Approval:** December 6th, 2023

**Minutes submitted by:** Claire Stauter, Kepro